Guardant Health prices $500 million convertible notes offering
Guardant Health Inc. (GH) priced $500M in convertible senior notes due 2032, with a 0% interest rate. The notes carry a conversion price of $208.95, a 35% premium over Tuesday's closing price. The company plans to use proceeds to repurchase existing notes and fund capped call transactions. Net proceeds are estimated at $489.3M, or $538.3M if the option is exercised.
How this was made
The 30-second read
Why it matters
The note pricing provides near $490M net proceeds, enabling debt repayment and capped call transactions, but introduces conversion risk.
Market read
First disclosure of a sizable convertible note offering, likely to move GH stock as investors assess dilution and cash use.
What to watch
The option to purchase additional $50M could increase total dilution if exercised, and the capped call transactions add further complexity.
Background
Guardant Health is a liquid biopsy company seeking to refinance existing debt and fund operations.
Ticker impact
Guardant Health announced pricing of $500M convertible senior notes, a fresh capital raise not previously disclosed.
likely downward pressure as market prices in dilution and increased debt.
Large $500M raise at a premium indicates significant cash influx but conversion terms may dilute equity, prompting a sell-off.
Market effects
May affect other biotech firms using convertible financing, highlighting market appetite for such structures.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond investors tracking convertible note trends.
Counterpoint
The premium conversion price suggests limited upside for noteholders, potentially making the raise less dilutive than perceived.
Key entities
- companyGuardant Health Inc.
Issuer of the convertible notes.
